

**REGULATED INFORMATION**

**ThromboGenics Raises €0.6 Million from the Exercise of Warrants**

**Leuven, Belgium – March 25, 2010** – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, today announces that it has raised € 0.6 million as the result of the exercise of warrants by a number of the Company's employees. The 96.667 shares created as a result of this warrant exercise are now listed on Euronext Brussels. Following this transaction, ThromboGenics now has 29.156.234 shares outstanding.

**- End -**

**For further information please contact:**

**ThromboGenics**

Chris Buyse, CFO

Tel: + 32 16 75 13 10  
[chris.buyse@thrombogenics.com](mailto:chris.buyse@thrombogenics.com)

**Citigate Dewe Rogerson**

Amber Bielecka/ David Dible/ Nina Enegren

Tel: +44 (0) 207 638 95 71  
[amber.bielecka@citigatedr.co.uk](mailto:amber.bielecka@citigatedr.co.uk)

**About ThromboGenics**

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PIGF) for cancer.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at [www.thrombogenics.com](http://www.thrombogenics.com).

***Important information about forward-looking statements***

*Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an*



*obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.*